Countdown to Ethereum Pectra Upgrade Activation: Learn more
$3.08T
Total marketcap
$91.75B
Total volume
BTC 61.17%     ETH 7.16%
Dominance

Ionis Pharmaceuticals IONS Stock

29.74 USD {{ price }} 0.134677% {{change_pct}}%
Exchange
NasdaqGS
Market Cap
4.73B USD
LOW - HIGH [24H]
29.48 - 30.09 USD
VOLUME [24H]
1.48M USD
{{ volume }}
P/E Ratio
0
Earnings per share
-3.04 USD

Ionis Pharmaceuticals Price Chart

Ionis Pharmaceuticals IONS Financial and Trading Overview

Ionis Pharmaceuticals stock price 29.74 USD
Previous Close 33.21 USD
Open 33.09 USD
Bid 30.37 USD x 200
Ask 32.3 USD x 100
Day's Range 32.26 - 33.46 USD
52 Week Range 32.26 - 52.49 USD
Volume 2.14M USD
Avg. Volume 1.43M USD
Market Cap 5.1B USD
Beta (5Y Monthly) 0.392
PE Ratio (TTM) N/A
EPS (TTM) -3.04 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 61.32 USD

IONS Valuation Measures

Enterprise Value 4.6B USD
Trailing P/E N/A
Forward P/E -8.631016
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 6.3468113
Price/Book (mrq) 7.689376
Enterprise Value/Revenue 5.729
Enterprise Value/EBITDA -13.682

Trading Information

Ionis Pharmaceuticals Stock Price History

Beta (5Y Monthly) 0.392
52-Week Change -36.68%
S&P500 52-Week Change 22.67%
52 Week High 52.49 USD
52 Week Low 32.26 USD
50-Day Moving Average 36.06 USD
200-Day Moving Average 41.25 USD

IONS Share Statistics

Avg. Volume (3 month) 1.43M USD
Avg. Daily Volume (10-Days) 1.54M USD
Shares Outstanding 157.9M
Float 156.63M
Short Ratio 7
% Held by Insiders 0.76%
% Held by Institutions 103.19%
Shares Short 10.9M
Short % of Float 8.06%
Short % of Shares Outstanding 6.90%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2023
Most Recent Quarter (mrq) September 30, 2024
Next Fiscal Year End December 31, 2024

Profitability

Profit Margin -44.67%
Operating Margin (ttm) -111.092%
Gross Margin -14.30%
EBITDA Margin -41.87%

Management Effectiveness

Return on Assets (ttm) -7.24%
Return on Equity (ttm) -73.38%

Income Statement

Revenue (ttm) 803.07M USD
Revenue Per Share (ttm) 5.5 USD
Quarterly Revenue Growth (yoy) -7.19%
Gross Profit (ttm) -114912000 USD
EBITDA -336270016 USD
Net Income Avi to Common (ttm) -358811008 USD
Diluted EPS (ttm) -2.44
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 2.49B USD
Total Cash Per Share (mrq) 15.78 USD
Total Debt (mrq) 1.99B USD
Total Debt/Equity (mrq) 301.12 USD
Current Ratio (mrq) 8.911
Book Value Per Share (mrq) 4.198

Cash Flow Statement

Operating Cash Flow (ttm) -351943008 USD
Levered Free Cash Flow (ttm) -171627744 USD

Profile of Ionis Pharmaceuticals

Country United States
State CA
City Carlsbad
Address 2855 Gazelle Court
ZIP 92010
Phone 760 931 9200
Website https://www.ionispharma.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 927

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Q&A For Ionis Pharmaceuticals Stock

What is a current IONS stock price?

Ionis Pharmaceuticals IONS stock price today per share is 29.74 USD.

How to purchase Ionis Pharmaceuticals stock?

You can buy IONS shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Ionis Pharmaceuticals?

The stock symbol or ticker of Ionis Pharmaceuticals is IONS.

Which industry does the Ionis Pharmaceuticals company belong to?

The Ionis Pharmaceuticals industry is Biotechnology.

How many shares does Ionis Pharmaceuticals have in circulation?

The max supply of Ionis Pharmaceuticals shares is 158.96M.

What is Ionis Pharmaceuticals Price to Earnings Ratio (PE Ratio)?

Ionis Pharmaceuticals PE Ratio is now.

What was Ionis Pharmaceuticals earnings per share over the trailing 12 months (TTM)?

Ionis Pharmaceuticals EPS is -3.04 USD over the trailing 12 months.

Which sector does the Ionis Pharmaceuticals company belong to?

The Ionis Pharmaceuticals sector is Healthcare.

Ionis Pharmaceuticals IONS included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 17366.13 USD
-0.1
9.58B USD 17128.71 USD 17467.35 USD 9.58B USD
Dow Jones U.S. Biotechnology In DJUSBT 2546.24 USD
+1.18
112.43M USD 2520.89 USD 2551.19 USD 112.43M USD
NASDAQ Biotechnology Total Retu XNBI 4527.84 USD
+1.29
4484.64 USD 4546.65 USD
NASDAQ Global Select Market Com NQGS 8495.19 USD
-0.11
8378.66 USD 8543.96 USD
NASDAQ DM Ex Japan Large Mid Ca NQDMXJPLMAUD 2100.38 AUD 1390.15 USD
<0.01
2100.38 AUD 1390.15 USD 2100.38 AUD 1390.15 USD
NASDAQ Biotechnology NBI 4184.77 USD
+1.29
4144.83 USD 4202.15 USD
NASDAQ HealthCare IXHC 931.02 USD
+0.81
921.75 USD 934.48 USD
Nasdaq US Smart Pharmaceuticals NQSSPH 1352.76 USD
+1.11
1340.2 USD 1356.44 USD
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG 2765.32 USD
+0.46
2735.39 USD 2775.41 USD
Stlmt ID NASDAQ Biotechnology NBX 4157.43 USD
+0.21
3927.42 USD 4157.43 USD